Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MorphoSys in-licenses antibody IP

Dyax (DYAX) granted MorphoSys (FSE:MOR) a license to IP covering the use of phage display

Read the full 154 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE